Lonza Group AG stock (CH0013841017): Swiss biotech leader in CDMO services

Lonza Group AG reported steady progress in its biopharmaceutical services during the first quarter of 2026, with expansions in US manufacturing capacity supporting key clients in mRNA and cell therapies. The company, listed on the SIX Swiss Exchange, maintains a strong position serving US biotech firms, according to Lonza Investor Relations as of 05/12/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Lonza Group AG: core business model

Lonza Group AG specializes in contract development and manufacturing organization (CDMO) services for the pharmaceutical and biotech industries. The company provides end-to-end solutions from drug substance development to commercial manufacturing, focusing on biologics, cell and gene therapies, and viral vectors. With facilities across Switzerland, the US, and Europe, Lonza supports over 1,000 clients globally, including major US biotechs developing therapies for cancer and rare diseases.

The business model emphasizes long-term partnerships, with revenue derived from milestone payments, manufacturing fees, and royalties. Lonza's expertise in continuous manufacturing and single-use technologies reduces costs for clients, making it a preferred partner for scaling innovative therapies. US investors track Lonza for its exposure to the booming $50 billion CDMO market, projected to grow 12% annually through 2030 per industry reports.

Main revenue and product drivers for Lonza Group AG

Lonza's primary revenue comes from its Biologics unit, which accounted for approximately 60% of group sales in 2025 full-year results published March 2026, generating CHF 3.5 billion from mammalian cell culture and biosimilars. Cell & Gene Technologies contributes 25%, driven by demand for viral vectors and exosomes used in personalized medicines. The Capsugeling segment adds stability with oral drug delivery systems.

Key growth drivers include capacity expansions at US sites in Portsmouth, New Hampshire, and Houston, Texas, adding 200kL of mammalian capacity by mid-2026. These investments target US clients like Moderna and Novartis, bolstering Lonza's role in the US mRNA vaccine supply chain post-COVID. Small molecule APIs remain a steady base, with 15% margins reported in Q1 2026 updates.

Industry trends and competitive position

The global CDMO sector is expanding rapidly due to patent cliffs and biotech funding resurgence, with US firms outsourcing 70% of manufacturing per IQVIA data from Q4 2025. Lonza competes with Catalent, Samsung Biologics, and WuXi Biologics but leads in end-to-end cell/gene capabilities, holding 20% market share in viral vectors according to IQVIA as of 12/2025.

Lonza's competitive edge lies in its integrated platform, from discovery to commercialization, and sustainability initiatives like carbon-neutral manufacturing by 2030. In the US, where biologics represent 40% of new drug approvals, Lonza's FDA-approved facilities position it favorably against pure-play rivals.

Why Lonza Group AG matters for US investors

Lonza Group AG offers US investors indirect exposure to biotech innovation without single-drug risk, as it serves 30% of the top 20 US pharma firms. Its US revenue share exceeds 40%, tied to domestic demand for advanced therapies amid IRA incentives for local manufacturing. The stock's CHF listing provides currency diversification, with ADRs available over-the-counter for easier access.

With the US cell/gene market valued at $15 billion in 2025 per EvaluatePharma, Lonza's expansions align with policy shifts favoring onshoring, making it relevant for portfolios focused on healthcare infrastructure.

Conclusion

Lonza Group AG remains a cornerstone in the biopharma CDMO space, with robust demand from US clients fueling capacity growth and revenue stability. While facing competition and capex pressures, its diversified portfolio and tech leadership support long-term resilience. Investors monitor upcoming Q2 results for updates on utilization rates and new contracts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.